MedTrace Logo

Intravenous Voriconazole in Patients With Renal Compromise

NCT00332410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-06-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether patients with compromised renal function (CrCl \< 50mL/min) receiving intravenous voriconazole experienced any adverse effects related to serum chemistries or other imaging studies of the kidney due to the potential accumulation of the vehicle cyclodextran.

Conditions

  • Renal Transplant

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Brian Potoski, Pharm D · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332410 on ClinicalTrials.gov